# Eastern Cooperative Oncology Group: Phase 3 study closed enrollment, 540 enrolled (Brain and Central Nervous System Tumors, Neurotoxicity)

**Score:** 55/100

| Field | Value |
|---|---|
| Sponsor | Eastern Cooperative Oncology Group |
| Sponsor type | Research network |
| Study | Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma |
| NCT ID | NCT00978458 |
| Phase | Phase 3 |
| Status | active not recruiting |
| Conditions | Brain and Central Nervous System Tumors; Neurotoxicity |
| Intervention types | drug, radiation |
| Target enrollment | 540 |
| Site countries | United States |
| Posted | 2009-09-17 |
| Planned start | 2009-11-17 |
| Event | Enrollment closed (active, not recruiting) |
| Event date | 2026-10-05 |
| Last update posted | 2026-10-05 |

## Why this score
- Enrollment closed: data management, monitoring and closeout ahead.
- Phase 3: multi-site, larger budget.
- 540 participants planned.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT00978458). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.